Researchers are reporting promising results for people with mesothelioma who can have surgery. One researcher tested immunotherapy before and after surgery while the other researcher studied a blood test that helps doctors detect mesothelioma earlier than scans. Doctors at several cancer centers, including Johns Hopkins, ran an early clinical trial[…]
Opdivo (nivolumab)
Immunotherapy Benefits and Drawbacks for Treating Mesothelioma
Mesothelioma is a rare and aggressive cancer that creates multiple challenges for patients and caregivers. Immune checkpoint inhibitors have recently shown promise to bring hope to people suffering from this devastating cancer. New data from Australia, however, is questioning their effectiveness and safety. Patients and caregivers must understand immunotherapy and[…]
Immunotherapy Might Not Be a Good Option for Mesothelioma
Mesothelioma is a rare and aggressive cancer mainly caused by asbestos exposure that creates challenges for patients and caregivers. Immune checkpoint inhibitors have brought hope to patients, but new data from Australia is raising questions about their safety and effectiveness. In order to make informed decisions, patients must understand all[…]
Immune Checkpoint Inhibitors for the Treatment of Mesothelioma
Mesothelioma is a rare, aggressive cancer mainly caused by asbestos exposure. One treatment that is giving hope to patients and caregivers is the use of immune checkpoint inhibitors. A new study from Australia has raised questions about the effectiveness and safety of this novel treatment. In order to best care[…]
Ipilimumab and Nivolumab for the Treatment of Mesothelioma
Mesothelioma is a difficult diagnosis to receive. With this diagnosis comes treatment regimens and their effects on the body. The United Kingdom has a new set of standard treatments for mesothelioma which include Ipilimumab and Nivolumab. A new article in the journal Lung Cancer reviews Ipilimumab and Nivolumab results, using[…]
Chemoimmunotherapy Benefits Pleural Mesothelioma Patients
Results from a phase 3 clinical trial were recently published in the Journal of Clinical Oncology showing that a combination of chemotherapy and immunotherapy for mesothelioma improves patients’ survival more than chemotherapy alone. Researchers combined Keytruda, or pembrolizumab, with platinum and pemetrexed chemotherapy. The overall response rate for patients receiving[…]
Opdivo and Yervoy After Mesothelioma Surgery Improves Survival
There might be more options for treating mesothelioma. A study looked at the combination of Opdivo and Yervoy after surgery. The study was performed at the Hyogo College of Medicine in Japan. Opdivo and Yervoy, which were recently approved for the treatment of mesothelioma, improved survival when administered after surgery.[…]
Keytruda as a Second Line Treatment for Mesothelioma
A new second line treatment has been developed for pleural mesothelioma. The treatment was created at the Netherlands Cancer Institute in Amsterdam. Research was done as a single-arm, open-label clinical trial combining pembrolizumab (Keytruda) and lenvatinib. The results were presented at the IASCL 2022 World Conference on Lung Cancer in[…]
SMARTEST Trial Hopes to Improve Survival Times for Mesothelioma
Researchers are performing a clinical trial hoping that they can make pleural mesothelioma a more manageable, and even survivable, disease. The clinical trial is being done at Princess Margaret Cancer Center in Toronto. The trial is known as SMARTEST, which stands for Surgery for Mesothelioma After Radiation Therapy using Exquisite[…]
Galinpepimut-S Cancer Vaccine in Combination with Opdivo
Promising results from a study on pleural mesothelioma were recently released. The study found when patients were treated with a new combination treatment, patients lived longer and had a better quality of life. The phase I clinical trial utilized a targeted cancer vaccine known as galinpepimut-S (GPS) and the immunotherapy[…]
Skip to content